{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:08:55Z","timestamp":1792800535061,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Tianjin Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["22JCQNJC00820"],"award-info":[{"award-number":["22JCQNJC00820"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Municipal Science and Technology Commission Grant","award":["21JCQNJC00070"],"award-info":[{"award-number":["21JCQNJC00070"]}],"id":[{"id":"https:\/\/ror.org\/03wb1xh22","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Tianjin Key Medical Discipline(Specialty) Construction Project","award":["TJYXZDXK-056B"],"award-info":[{"award-number":["TJYXZDXK-056B"]}]},{"name":"Key projects of Tianjin Applied Basic Research and Multi-Investment Fund","award":["21JCZDJC01240"],"award-info":[{"award-number":["21JCZDJC01240"]}]},{"name":"Science and Technology Project of Tianjin Municipal Health Committee","award":["TJWJ2022XK018"],"award-info":[{"award-number":["TJWJ2022XK018"]}]},{"name":"the Key Science and Technology Support Project of Tianjin Science and Technology Bureau","award":["20YFZCSY00800"],"award-info":[{"award-number":["20YFZCSY00800"]}]},{"name":"General Project of National Natural Science Foundation of China","award":["81970180"],"award-info":[{"award-number":["81970180"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Interferon-induced protein with tetratricopeptide repeat (IFIT) family, IFIT1\/2\/3\/5, play an important role in different tumors progression. However, the prognosis significance and biological role of IFIT family members in acute myeloid leukemia (AML) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We obtained the gene expression data and clinical information of 173 AML patients from The Cancer Genome Atlas (TCGA) database. Several databases were used in our study, including GEPIA, MethSurv, STRING, GSCA and GeneMANIA database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mRNA expression of IFIT1\/2\/3\/5 was elevated in AML patients and had a high ability to distinguish AML from controls based on the receiver operating characteristic (ROC) curve (AUC\u2009&gt;\u20090.9). Kaplan\u2013Meier survival analysis showed that higher levels of IFIT2\/3\/5 expression predict poor prognosis in AML patients. Besides, the DNA methylation analysis suggested that 7 CpG sites of IFIT2, 4 CpG sites of IFIT3 and 10 CpG sites of IFIT5 were significantly associated with the prognosis of AML patients. In addition, IFIT2\/3\/5 expression was significantly positively associated with the immune cell infiltration and immune checkpoint expression, such as CTLA4, PDCD1, LAG3, and TIGIT. Finally, drug sensitivity analysis revealed that AML patients with high expression of IFIT2\/3\/5 were resistant to multiple drugs, but sensitive to dasatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IFIT family genes might serve as biomarkers for diagnosis, prognosis and drug sensitivity in AML patients. The activation or blocking of IFIT-related signaling pathways may provide novel insights into immunotherapy for patients with AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-023-01735-0","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:02:37Z","timestamp":1700298157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The diagnostic\/prognostic roles and biological function of the IFIT family members in acute myeloid leukemia"],"prefix":"10.1186","volume":"16","author":[{"given":"YiFan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenYi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RuiTing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinPing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MingFeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"7","key":"1735_CR2","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/ni1080","volume":"5","author":"KJ Hope","year":"2004","unstructured":"Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5(7):738\u201343.","journal-title":"Nat Immunol"},{"issue":"24","key":"1735_CR3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345.","journal-title":"Blood"},{"issue":"12","key":"1735_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"1735_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40164-023-00409-y","volume":"12","author":"X Suo","year":"2023","unstructured":"Suo X, Zheng F, Wang D, et al. Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial. Experimental hematology & oncology. 2023;12(1):45.","journal-title":"Experimental hematology & oncology."},{"issue":"6","key":"1735_CR6","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaoncol.2015.0617","volume":"1","author":"TM Kadia","year":"2015","unstructured":"Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review. JAMA Oncol. 2015;1(6):820\u20138.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1735_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131\u201344.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"1735_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6(11):836\u201348.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"1735_CR9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","volume":"21","author":"L Thyrell","year":"2002","unstructured":"Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21(8):1251\u201362.","journal-title":"Oncogene"},{"issue":"6","key":"1735_CR10","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1189\/jlb.69.6.912","volume":"69","author":"MJ de Veer","year":"2001","unstructured":"de Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol. 2001;69(6):912\u201320.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"1735_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/jir.2010.0101","volume":"31","author":"V Fensterl","year":"2011","unstructured":"Fensterl V, Sen GC. The ISG56\/IFIT1 gene family. J Interferon Cytokine Res. 2011;31(1):71\u20138.","journal-title":"J Interferon Cytokine Res"},{"issue":"7435","key":"1735_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature11783","volume":"494","author":"YM Abbas","year":"2013","unstructured":"Abbas YM, Pichlmair A, G\u00f3rna MW, Superti-Furga G, Nagar B. Structural basis for viral 5\u2019-PPP-RNA recognition by human IFIT proteins. Nature. 2013;494(7435):60\u20134.","journal-title":"Nature"},{"issue":"5","key":"1735_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1110\/ps.062092506","volume":"15","author":"AL Cortajarena","year":"2006","unstructured":"Cortajarena AL, Regan L. Ligand binding by TPR domains. Protein Sci. 2006;15(5):1193\u20138.","journal-title":"Protein Sci"},{"issue":"2","key":"1735_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.str.2009.11.015","volume":"18","author":"C-L Keiski","year":"2010","unstructured":"Keiski C-L, Harwich M, Jain S, et al. AlgK is a TPR-containing protein and the periplasmic component of a novel exopolysaccharide secretin. Structure. 2010;18(2):265\u201373.","journal-title":"Structure"},{"issue":"23","key":"1735_CR15","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.1073\/pnas.83.23.8929","volume":"83","author":"D Levy","year":"1986","unstructured":"Levy D, Larner A, Chaudhuri A, Babiss LE, Darnell JE. Interferon-stimulated transcription: isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci USA. 1986;83(23):8929\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1735_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41419-019-1669-z","volume":"10","author":"J Huang","year":"2019","unstructured":"Huang J, Lo UG, Wu S, et al. The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression. Cell Death Dis. 2019;10(6):437.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1735_CR17","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.18632\/oncotarget.2494","volume":"6","author":"H Niess","year":"2015","unstructured":"Niess H, Camaj P, Mair R, et al. Overexpression of IFN-induced protein with tetratricopeptide repeats 3 (IFIT3) in pancreatic cancer: cellular \u201cpseudoinflammation\u201d contributing to an aggressive phenotype. Oncotarget. 2015;6(5):3306\u201318.","journal-title":"Oncotarget"},{"issue":"1","key":"1735_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000486219","volume":"45","author":"L Chen","year":"2018","unstructured":"Chen L, Zhai W, Zheng X, et al. Decreased IFIT2 Expression Promotes Gastric Cancer Progression and Predicts Poor Prognosis of the Patients. Cell Physiol Biochem. 2018;45(1):15\u201325.","journal-title":"Cell Physiol Biochem"},{"issue":"19","key":"1735_CR19","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/onc.2016.418","volume":"36","author":"H Jia","year":"2017","unstructured":"Jia H, Song L, Cong Q, et al. The LIM protein AJUBA promotes colorectal cancer cell survival through suppression of JAK1\/STAT1\/IFIT2 network. Oncogene. 2017;36(19):2655\u201366.","journal-title":"Oncogene"},{"issue":"4","key":"1735_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2011-02-334748","volume":"118","author":"V Rockova","year":"2011","unstructured":"Rockova V, Abbas S, Wouters BJ, et al. Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood. 2011;118(4):1069\u201376.","journal-title":"Blood"},{"issue":"1","key":"1735_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1735_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947\u201351.","journal-title":"Protein Sci"},{"issue":"4","key":"1735_CR23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782\u201395.","journal-title":"Immunity"},{"key":"1735_CR24","doi-asserted-by":"crossref","unstructured":"Pidugu VK, Wu M-M, Pidugu HB, Lee T-C. IFIT1 and IFIT3 modulate the drug response in human oral squamous cell carcinoma through interaction and activation of Hsp90. Cancer Res. 2019;79(13):Sabcs18-2098.","DOI":"10.1158\/1538-7445.AM2019-2098"},{"issue":"25","key":"1735_CR25","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.2174\/0929867328666210617105209","volume":"28","author":"XF Tan","year":"2021","unstructured":"Tan XF, Chen Q, Hua SH, Yip GW. Roles of Interferon Induced Protein with Tetratricopeptide Repeats (IFIT) Family in Cancer. Curr Med Chem. 2021;28(25):5034\u201347.","journal-title":"Curr Med Chem"},{"key":"1735_CR26","doi-asserted-by":"crossref","unstructured":"Zhang W, Li Y, Xin S, et al. The emerging roles of IFIT3 in antiviral innate immunity and cellular biology. J Med Virol. 2022;95:e28259.","DOI":"10.1002\/jmv.28259"},{"issue":"1","key":"1735_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/hep.29156","volume":"66","author":"Y Yang","year":"2017","unstructured":"Yang Y, Zhou Y, Hou J, et al. Hepatic IFIT3 Predicts Interferon-alpha Therapeutic Response in Patients of Hepatocellular Carcinoma. Hepatology. 2017;66(1):152\u201366.","journal-title":"Hepatology"},{"key":"1735_CR28","doi-asserted-by":"crossref","unstructured":"Jiang Y, Zhang C, Zhang J, Han D, Shi X. Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma. Int Immunopharmacol. 2021;101(Pt A):108344.","DOI":"10.1016\/j.intimp.2021.108344"},{"issue":"23","key":"1735_CR29","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"1735_CR30","doi-asserted-by":"publisher","first-page":"11988","DOI":"10.18632\/aging.202901","volume":"13","author":"K Li","year":"2021","unstructured":"Li K, Chen L, Zhang H, et al. High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia. Aging. 2021;13(8):11988\u20132006.","journal-title":"Aging"},{"issue":"9","key":"1735_CR31","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1074\/jbc.M110.207068","volume":"286","author":"M Stawowczyk","year":"2011","unstructured":"Stawowczyk M, Van Scoy S, Kumar KP, Reich NC. The Interferon Stimulated Gene 54 Promotes Apoptosis. J Biol Chem. 2011;286(9):7257\u201366.","journal-title":"J Biol Chem"},{"key":"1735_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1186\/1471-2407-14-633","volume":"14","author":"X Feng","year":"2014","unstructured":"Feng X, Wang Y, Ma Z, et al. MicroRNA-645, up-regulated in human adencarcinoma of gastric esophageal junction, inhibits apoptosis by targeting tumor suppressor IFIT2. BMC Cancer. 2014;14:633.","journal-title":"BMC Cancer"},{"key":"1735_CR33","doi-asserted-by":"crossref","unstructured":"Hsu Y-L, Shi S-F, Wu W-L, Ho L-J, Lai J-H. Protective roles of Interferon-Induced Protein with Tetratricopeptide Repeats 3 (IFIT3) in dengue virus infection of human lung epithelial cells. PLoS One. 2013;8(11):e79518.","DOI":"10.1371\/journal.pone.0079518"},{"issue":"9","key":"1735_CR34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/ijc.33908","volume":"150","author":"S Ganesan","year":"2022","unstructured":"Ganesan S, Mathews V, Vyas N. Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? Int J Cancer. 2022;150(9):1401\u201311.","journal-title":"Int J Cancer"},{"issue":"2","key":"1735_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000500315","volume":"143","author":"Y Li","year":"2020","unstructured":"Li Y, You MJ, Yang Y, Hu D, Tian C. The Role of Tumor-Associated Macrophages in Leukemia. Acta Haematol. 2020;143(2):112\u20137.","journal-title":"Acta Haematol"},{"issue":"1","key":"1735_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000500588","volume":"143","author":"Z Guo","year":"2020","unstructured":"Guo Z, Chen Z, Xu Y, et al. The Association of Circulating T Follicular Helper Cells and Regulatory Cells with Acute Myeloid Leukemia Patients. Acta Haematol. 2020;143(1):19\u201325.","journal-title":"Acta Haematol"},{"issue":"8","key":"1735_CR37","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/cas.12459","volume":"105","author":"Y Han","year":"2014","unstructured":"Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci. 2014;105(8):933\u201342.","journal-title":"Cancer Sci"},{"issue":"6","key":"1735_CR38","first-page":"7031","volume":"14","author":"Y Jia","year":"2017","unstructured":"Jia Y, Zhang C, Hua M, Wang M, Chen P, Ma D. Aberrant NLRP3 inflammasome associated with aryl hydrocarbon receptor potentially contributes to the imbalance of T-helper cells in patients with acute myeloid leukemia. Oncol Lett. 2017;14(6):7031\u201344.","journal-title":"Oncol Lett"},{"issue":"1","key":"1735_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen C, Liang C, Wang S, et al. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):28.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1735_CR40","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1172\/JCI129204","volume":"130","author":"L Vago","year":"2020","unstructured":"Vago L, Gojo I. Immune escape and immunotherapy of acute myeloid leukemia. J Clin Invest. 2020;130(4):1552\u201364.","journal-title":"J Clin Invest"},{"issue":"2","key":"1735_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, et al. Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397-404.e399.","journal-title":"Cell"},{"key":"1735_CR42","doi-asserted-by":"crossref","unstructured":"Simonicova K, Janotka L, Kavcova H, Sulova Z, Breier A, Messingerova L. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resist Updat. 2022;61:100805.","DOI":"10.1016\/j.drup.2022.100805"},{"key":"1735_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fmolb.2019.00148","volume":"6","author":"VK Pidugu","year":"2019","unstructured":"Pidugu VK, Pidugu HB, Wu M-M, Liu C-J, Lee T-C. Emerging functions of human IFIT proteins in cancer. Front Mol Biosci. 2019;6:148.","journal-title":"Front Mol Biosci"},{"key":"1735_CR44","doi-asserted-by":"crossref","unstructured":"Yen A-H, Chen Y-C, Pidugu VK, Liu C-J, Lee T-C. Association of Interferon-induced protein with tetratricopeptide repeats 1 and 3 expression with regional metastasis and drug resistance in oral squamous cell carcinoma. Cancer Res. 2014;74(19):AM2014-40.","DOI":"10.1158\/1538-7445.AM2014-40"},{"issue":"17","key":"1735_CR45","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/s41388-018-0662-9","volume":"38","author":"VK Pidugu","year":"2019","unstructured":"Pidugu VK, Wu M-M, Yen A-H, et al. IFIT1 and IFIT3 promote oral squamous cell carcinoma metastasis and contribute to the anti-tumor effect of gefitinib via enhancing p-EGFR recycling. Oncogene. 2019;38(17):3232\u201347.","journal-title":"Oncogene"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01735-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T09:21:45Z","timestamp":1700299305000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01735-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01735-0","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TCGA and GEO belong to public databases. The patients involved in the database have obtained ethical approval. Users can download relevant data for free for research and publish relevant articles. Our study is based on open source data, so there are no ethical issues and other conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"296"}}